Distribuzione geografica
Continente #
NA - Nord America 894
EU - Europa 765
AS - Asia 292
OC - Oceania 4
SA - Sud America 4
Totale 1959
Nazione #
US - Stati Uniti d'America 821
IT - Italia 427
CN - Cina 254
UA - Ucraina 90
RU - Federazione Russa 89
CA - Canada 73
FR - Francia 34
DE - Germania 28
VN - Vietnam 22
GB - Regno Unito 21
NL - Olanda 17
SE - Svezia 13
ES - Italia 11
CH - Svizzera 9
GR - Grecia 7
UZ - Uzbekistan 7
AT - Austria 6
AU - Australia 4
IN - India 4
PL - Polonia 4
CL - Cile 3
CZ - Repubblica Ceca 3
HU - Ungheria 3
BG - Bulgaria 2
IR - Iran 2
EC - Ecuador 1
HK - Hong Kong 1
IL - Israele 1
JP - Giappone 1
RO - Romania 1
Totale 1959
Città #
Chandler 169
Catania 124
Jacksonville 104
Nanjing 94
Andover 89
Cambridge 88
Lawrence 88
Houston 63
Toronto 57
Des Moines 48
Saint Petersburg 27
Wilmington 27
Nanchang 23
Hebei 22
Dong Ket 18
Jiaxing 18
Shenyang 17
Ottawa 16
Changsha 13
Grafing 13
Centro 12
Leawood 12
Madrid 11
Beijing 10
Tianjin 10
Redmond 8
Moscow 7
Ningbo 7
Norwalk 7
Palermo 7
Amsterdam 6
Den Haag 6
Jinan 6
Kunming 6
Redwood City 6
Scafati 6
Civitavecchia 5
Groningen 5
Guangzhou 5
Padova 5
Raffadali 5
San Mateo 5
Zhengzhou 5
Ann Arbor 4
Augusta 4
Castelvetrano 4
Hangzhou 4
Hanoi 4
Latina 4
Marseille 4
Mountain View 4
Pozzo Di Gotto 4
San Francisco 4
Aci Catena 3
Acireale 3
Bari 3
Budapest 3
Dearborn 3
Fuzhou 3
Gela 3
Messina 3
New Haven 3
Porto San Giorgio 3
Randazzo 3
Riposto 3
Santiago 3
Villamagna 3
Ardabil 2
Biancavilla 2
Bologna 2
Cergy 2
Chioggia 2
Como 2
Desio 2
Falls Church 2
Foggia 2
Frankfurt Am Main 2
Ghisalba 2
Haikou 2
Kiev 2
Ludwigshafen 2
Marano Principato 2
Marsala 2
Melbourne 2
Rome 2
Simeri 2
Simi Valley 2
Trecastagni 2
Alcamo 1
Ashburn 1
Belpasso 1
Bronte 1
Bucharest 1
Canberra 1
Castiglione Di Sicilia 1
Central 1
Changchun 1
Cracow 1
Giarre 1
Haifa 1
Totale 1416
Nome #
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 82
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 74
Design, synthesis, and pharmacological evaluation of NO donor-sigma receptors hybrids for the treatment of cancer 59
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 57
Combination of heme oxygenase-1 inhibition and sigma receptor modulation for anticancer activity 48
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 42
S2RSLDB: A comprehensive manually curated, internet-accessible database of the sigma-2 receptor selective ligands 41
Sigma-2 receptor ligands QSAR model dataset 39
Development of Sigma Receptors Nitric Oxide Photodonor Ligands with Antiproliferative Activity 38
Fourfold filtered statistical/computational approach for the identification of imidazole compounds as HO-1 inhibitors from natural products 38
Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform 1 Inhibitors 36
Synthesis of “no-light activated” Ciprofloxacin and Norfloxacin derivatives as potential biofilm dispersant agents 36
DNA intercalators based on (1,10-phenanthrolin-2-yl)isoxazolidin-5-yl core with better growth inhibition and selectivity than cisplatin upon head and neck squamous cells carcinoma 33
Molecular modeling studies of pseudouridine isoxazolidinyl nucleoside analogues as potential inhibitors of the pseudouridine 5'-monophosphate glycosidase 32
Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors 31
(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties 31
Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells 31
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 31
Antioxidant activity of (+)-Pentazocine on activated microglia 30
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 30
4-Nitro-2,1,3-benzoxadiazole derivatives as potential fluorescent sigma receptor probes 30
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 30
Novel structural insight into inhibitors of heme oxygenase-1 (ho-1) by new imidazole-based compounds: Biochemical and in vitro anticancer activity evaluation 30
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 30
[1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT7 receptor 30
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 29
Design and synthesis of new benzomorphan LP1 analogues, an opioid ligand with low development of tolerance 29
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review 29
Heme Oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia 29
Comprehensive data on a 2D-QSAR model for Heme Oxygenase isoform 1 inhibitors 29
A pseudouridine isoxazolidinyl nucleoside analogue structural analysis: A morphological approach 29
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 28
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 28
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 28
Tumor Targeting Sigma Receptor Ligands: Development of New Molecular Hybrids as Anticancer Therapeutics 27
Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands 27
Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma 26
Antitrypanosomal lead discovery: Identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth 26
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 26
La modellistica molecolare applicata ai recettori Sigma-1 e Sigma-2: un excursus 26
Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation 26
Synthesis of Novel Benzylpiperazine Derivatives as Ligands for the σ1 Receptor 24
A structure-and ligand-based virtual screening of a database of “small” marine natural products for the identification of “blue” sigma-2 receptor ligands 24
C-5'-Triazolyl-2'-oxa-3'-aza-4'a-carbanucleosides: Synthesis and biological evaluation 23
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 23
Heme Oxygenase-1 Inhibition: A Novel Strategy for the Design of Azole-Based Antitumour Agents 23
Development of NO-releasing sigma receptor hybrids as anticancer agents 23
Identification of Potentially Potent Heme Oxygenase 1 Inhibitors through 3D-QSAR Coupled to Scaffold-Hopping Analysis 23
Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors 22
Haloperidol Metabolite II Valproate Ester ( S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 22
Evaluation of N-substitution in 6,7-benzomorphan compounds 21
Composti inorganici [Cap. 6] 21
Novel Sigma Receptors Ligands-Nitric Oxide Photodonor: Molecular Hybrids for Double-Targeted Antiproliferative Effect 21
Morphing of ibogaine: A successful attempt into the search for sigma-2 receptor ligands 21
Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1) 20
Haloperidol Metabolite II Valproate Ester: Antiangiogenic Activity in Human Microvascular Retinal Endothelial Cells 20
Evaluation of human PDE4 inhibitors cilomilast and piclamilast as lead compounds for the treatment of human African trypanosomiasis (HAT) 20
In-vitro evaluation of a new benzomorphan-based ligand 20
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 20
New homo and hetero bis-arylpiperazine and bis-benzylpiperazine derivatives as 5-HT7R selective ligands: design and synthesis 20
Development of new benzomorphan LP1 analogues 20
Involvement of sigma 2 receptor on motor disorder 19
Repurposing of human kinase inhibitors in neglected protozoan diseases 19
Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents 19
New selective Sigma-1/HDACi prodrugs for neurodegenerative disorders 19
Development of novel H2S-donor sigma receptor hybrids for the management of pain. 19
Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors 19
Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors 18
Identification of Novel Lead Compounds for Sleeping Sickness via Preferred Lead Repurposing 18
Pain management: new long-acting opioid ligands 18
Novel selective ligands for the serotonergic 5-HT7 receptor: tricyclic derivatives Bearing the pyrimido-4(3H)-one ring 18
Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery 18
Synthesis and pharmacological evaluation of indole-based sigma receptor ligands 18
Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation 18
Synthesis and evaluation of haloperidol metabolite II prodrugs as anticancer agents 17
Identification of “Preferred” Human Kinase Inhibitors for Human African Trypanosomiasis Through a Statistical Analysis-Driven Approach 16
Neglected disease lead discovery: Profiling analogs of Lapatinib against the protozoan parasites that cause Chagas disease, leishmaniasis, and malaria 16
Targeting Neglected Parasitic Diseases with Human EGFR Inhibitor Chemotypes 16
Preparation and Evaluation of a Series of Indoles as Sigma Receptor Ligands 16
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 16
Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign 16
Identification of “Preferred” Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing? 16
CNS permeability parameters determination through a statistical analysis driven approach 16
New 5-Ht7 Receptor Ligands As Potential Antidepressant Agents. 14
null 14
Targeting Heme Oxygenase-1 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia 13
Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents 13
Tuning Properties for Blood-Brain Barrier Permeation: A Statistics-Based Analysis 13
Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H3 and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties 9
Interaction of new sigma ligands with biomembrane models evaluated by differential scanning calorimetry and Langmuir-Blodgett studies 4
Discovery of 3-(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligands 2
Totale 2329
Categoria #
all - tutte 3453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3453

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018253 001024 1430 4622 534509
2018/2019220 35007 459 399 305230
2019/2020433 169523017 1910 307 11353122
2020/2021361 1083544 1218 342 2054430
2021/2022719 611003117 1155 10531 422010182
2022/2023274 138126100 00 00 0000
Totale 2329